InGeNA will be making a submission into the review of the National Medicines Policy which opened on 30 October. The process is a high-level review aimed at identifying any gaps in the NMP’s objectives, partnership approach and accountabilities. The Discussion Paper is available here.
The consultation phase ends on 8 October.